Log In
BCIQ
Print this Print this
 

PRX-OTC

  Manage Alerts
Collapse Summary General Information
Company PhaseRx Inc.
DescriptionIntracellular enzyme replacement therapy
Molecular Target
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPreclinical
Standard IndicationUrea cycle disorder (UCD)
Indication DetailsTreat ornithine transcarbamylase deficiency (OTCD)
Regulatory Designation U.S. - Orphan Drug (Treat ornithine transcarbamylase deficiency (OTCD))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today